磷脂酰肌醇3- 激酶对心脏的调节

磷脂酰肌醇3-激酶(phosphatidylinosito1 3-kinase,PI3K)是体内很多生理过程中起关键作用的信号分子,PI3K介导的信号转导通路调节细胞的增生、分化、凋亡等活动。以往研究较多的是PI3K与肿瘤发生发展的关系,最近很多研究发现PI3K介导的信号转导通路对心脏具有重要的调节功能。本文就近年来关于PI3K的结构和功能以及PI3K对心脏的调节的研究作一综述。     

PI3K/Akt信号通路相关的生物学调控机制研究进展

PI3K/Akt信号通路是由酶联受体介导的信号转导通路,该通路不仅参与多种生长因子、细胞因子和细胞外基质等的信号转导,同时还参与细胞增殖、分化、凋亡和葡萄糖转运等多种细胞功能的调节,特别是在细胞凋亡、细胞存活以及调控细胞糖代谢等方面具有重要作用。本研究综述了PI3K-Akt信号通路的结构组成、通路活化、通信过程、调控机制及其生物学功能等方面的研究进展,为进一步研究PI3K/Akt信号通路的生物学调控作用机制提供启示。     

脑内膜雌激素受体信号转导与窖蛋白

雌激素受体在脑内分布十分广泛,对脑功能具有重要作用。雌激素可以通过膜雌激素受体启动的信号转导通路(非基因组效应)作用于中枢神经系统的很多部位,而窖蛋白(caveolin)可以通过不同方式参与膜雌激素受体介导的脑功能调节。简要综述了脑内膜雌激素受体介导的信号转导通路与窖蛋白相关的研究进展。     

β-arrestin与β-肾上腺素受体

2012年度诺贝尔化学奖授予了美国科学家罗伯特.莱夫科维茨（Robert J.Lefkowitz）和布莱恩.克比尔卡（Brian K.Kobilka）,以表彰他们在G蛋白偶联受体研究中的贡献。从Robert J.Lefkowitz最初研究β-肾上腺素受体（β-adrenergic receptor,β-AR）减敏机制时发现β-arrestin1至今已有20多年,随着对β-arrestin在细胞信号转导中作用研究的逐渐深入,发现β-arrestin参与β-AR的减敏、内化和降解;近年来又发现,依赖β-arrestin的β-AR信号转导通路具有＂偏向激活＂现象,并提示这种依赖β-arrestin的＂偏向激活＂信号转导通路具有心脏保护作用。β-肾上腺素受体阻滞剂的发现和临床应用被视为20世纪药物治疗学上里程碑式的进展,是药物防治心脏疾病的最伟大突破,很多心血管药物都以β-AR为靶点。但是,由于目前受体药物均是针对受体本身的调控,这样在阻断了受体介导的病理性信号通路和功能的同时,也阻断了受体介导的正常生理性信号通路和功能,造成了严重的毒副作用。所以,研发能选择性阻滞β-AR过度激活介导的病理性信号通路和功能的同时,保留受体介导的正常生理性信号通路和功能（如β-arrestin信号通路）的药物,对治疗心血管疾病有重要意义,受体功能选择性的配体药物将成为未来药物的研究方向。该文将回顾β-arrestin的发现过程,综述其与β-AR的相互作用,期望能为心脏疾病的药物治疗提供参考。     

TRB3——信号通路中一个新的脚手架蛋白

TRB3是近年来发现的一个具有脚手架样调控功能的蛋白质,在P13K/Akt、NF-кB、MAPK和ATF4/CHOP通路的信号转导以及调控中发挥了重要的作用,此外它还参与了泛素-蛋白酶体途径.     

P13K信号通路通过Skp2、p27调节肝癌细胞的增殖

探讨磷脂酰肌醇3-激酶（PI3K）信号通路调节肝癌细胞增殖的机制．用LY294002特异性阻断P13K信号通路后,人肝癌细胞（SMMC-7721）的增殖明显被抑制．RT-PCR及蛋白质印迹结果显示,LY294002增加了p27蛋白的表达,但不影响p27的mRNA表达．在LY294002处理的细胞中转入p27的RNAi质粒以干扰p27蛋白的表达后,肝癌细胞的增殖能力可部分恢复．放线菌酮（Chx）处理实验表明,阻断P13K信号通路使p27蛋白的半衰期延长,稳定性增加．进一步研究发现,LY294002可抑制介导p27蛋白降解的关键分子Skp2的rnRNA表达,还可缩短Skp2蛋白的半衰期,降低Skp2蛋白的稳定性．但在SMMC-7721中分别转染P13K下游重要靶分子Akt的持续激活和失活突变体,却并不影响p27蛋白的表达．这些结果表明,P13K信号通路在转录及翻译后水平调节Skp2的表达而影响p27蛋白的降解,从而调节肝癌细胞的增殖,但Akt并没有参与这种调节．     

支架蛋白Gab的结构与功能及其在肿瘤、炎症和心血管疾病发生中的作用北大核心CSCD

Gab家族蛋白(Grb2-associated binder family proteins)是生长因子受体结合蛋白2的结合蛋白。在哺乳动物中,Gab家族蛋白包括Gab1、Gab2和Gab3。该家族蛋白可通过介导膜受体与信号转导蛋白间的耦联及各信号分子间的相互作用参与信号转导,其主要是通过激活SHP2/RAS/ERK和PI3K/AKT两条经典的信号通路,进而参与一系列的生物应答。研究显示,Gab蛋白的表达或功能异常与肿瘤、炎症和心血管疾病的发生、发展密切相关。本文就Gab蛋白结构、参与信号转导的调节机制及其在肿瘤、炎症和心血管疾病发生、发展中的作用进行综述。     

支架蛋白Gab的结构与功能及其在肿瘤、炎症和心血管疾病发生中的作用

Gab家族蛋白(Grb2-associated binder family proteins)是生长因子受体结合蛋白2的结合蛋白。在哺乳动物中,Gab家族蛋白包括Gab1、Gab2和Gab3。该家族蛋白可通过介导膜受体与信号转导蛋白间的耦联及各信号分子间的相互作用参与信号转导,其主要是通过激活SHP2/RAS/ERK和PI3K/AKT两条经典的信号通路,进而参与一系列的生物应答。研究显示,Gab蛋白的表达或功能异常与肿瘤、炎症和心血管疾病的发生、发展密切相关。本文就Gab蛋白结构、参与信号转导的调节机制及其在肿瘤、炎症和心血管疾病发生、发展中的作用进行综述。     

正畸牙移动相关信号通路研究进展

<正>畸牙移动是在机械力的作用下,通过对牙周膜产生牵张或压缩的力来引起牙周组织在生理限度内的组织改建,从而达到牙齿移动、矫治畸形的目的。由于没有明显的年龄限制,正畸矫治在全球范围已变得越来越普遍。因此,相关的研究也日益增多。牙齿移动的生物学基础是正畸力作用于牙周组织激活一系列信号转导通路,进而引起牙周膜的修复改建。为指导临床、加速正畸矫治疗程提供新的思路,本文综述了近年来有关正畸牙移动相关信号通路的研究进展。发现最新的研究集中在MAPK信号通路,Wnt/β-catenin信号通路,PI3K/AKt/m TOR信号通路,BMP-2信号通路,Caspase-3介导的凋亡通路较多。但是正畸牙移动引起的牙周组织改建是一个多种生物力学信号转导通路相互调节相互作用的过程,对于上述信号通路之间的相互关系还有待于我们更进一步的探索。     

β-arrestin的生物学研究进展

β-arrestin 1和2是一类介导受体脱敏的重要可溶性蛋白质,对绝大部分与受体偶联G蛋白介导的信号转导具有重要调节作用,在G蛋白偶联受体(G protein-coupled receptors, GPCRs)脱敏、内化、复敏、细胞增殖反应和基因转录中具有重要地位.对β-arrestin介导的复杂信号通路的研究将揭示它们的调节功能对人类健康的影响,有助于开发新一代影响GPCRs的药物.     

A specific role of phosphatidylinositol 3-kinase gamma. A regulation of autonomic Ca(2)+ oscillations in cardiac cells

Purinergic stimulation of cardiomyocytes turns on a Src family tyrosine kinase-dependent pathway that stimulates PLCgamma and generates IP(3), a breakdown product of phosphatidylinositol 4,5-bisphosphate (PIP2). This signaling pathway closely regulates cardiac cell autonomic activity (i.e., spontaneous cell Ca(2+) spiking). PIP2 is phosphorylated on 3' by phosphoinositide 3-kinases (PI3Ks) that belong to a broad family of kinase isoforms. The product of PI3K, phosphatidylinositol 3,4,5-trisphosphate, regulates activity of PLCgamma. PI3Ks have emerged as crucial regulators of many cell functions including cell division, cell migration, cell secretion, and, via PLCgamma, Ca(2+) homeostasis. However, although PI3Kalpha and -beta have been shown to mediate specific cell functions in nonhematopoietic cells, such a role has not been found yet for PI3Kgamma.We report that neonatal rat cardiac cells in culture express PI3Kalpha, -beta, and -gamma. The purinergic agonist predominantly activates PI3Kgamma. Both wortmannin and LY294002 prevent tyrosine phosphorylation, and membrane translocation of PLCgamma as well as IP(3) generation in ATP-stimulated cells. Furthermore, an anti-PI3Kgamma, but not an anti-PI3Kbeta, injected in the cells prevents the effect of ATP on cell Ca(2+) spiking. A dominant negative mutant of PI3Kgamma transfected in the cells also exerts the same action. The effect of ATP was observed on spontaneous Ca(2+) spiking of wild-type but not of PI3Kgamma(2/2) embryonic stem cell-derived cardiomyocytes. ATP activates the Btk tyrosine kinase, Tec, and induces its association with PLCgamma. A dominant negative mutant of Tec blocks the purinergic effect on cell Ca(2+) spiking. Tec is translocated to the T-tubes upon ATP stimulation of cardiac cells. Both an anti-PI3Kgamma antibody and a dominant negative mutant of PI3Kgamma injected or transfected into cells prevent the latter event.We conclude that PI3Kgamma activation is a crucial step in the purinergic regulation of cardiac cell spontaneous Ca(2+) spiking. Our data further suggest that Tec works in concert with a Src family kinase and PI3Kgamma to fully activate PLCgamma in ATP-stimulated cardiac cells. This cluster of kinases provides the cardiomyocyte with a tight regulation of IP(3) generation and thus cardiac autonomic activity.     

Inhibitors of phosphatidylinositol 3'-kinases promote mitotic cell death in HeLa cells

The phosphatidylinositol 3-kinase (PI3K) pathway plays an important role in many biological processes, including cell cycle progression, cell growth, survival, actin rearrangement and migration, and intracellular vesicular transport. However, the involvement of the PI3K pathway in the regulation of mitotic cell death remains unclear. In this study, we treated HeLa cells with the PI3K inhibitors, 3-methyladenine (3-MA, as well as a widely used autophagy inhibitor) and wortmannin to examine their effects on cell fates using live cell imaging. Treatment with 3-MA decreased cell viability in a time- and dose-dependent manner and was associated with caspase-3 activation. Interestingly, 3-MA-induced cell death was not affected by RNA interference-mediated knockdown (KD) of beclin1 (an essential protein for autophagy) in HeLa cells, or by deletion of atg5 (an essential autophagy gene) in mouse embryonic fibroblasts (MEFs). These data indicate that cell death induced by 3-MA occurs independently of its ability to inhibit autophagy. The results from live cell imaging studies showed that the inhibition of PI3Ks increased the occurrence of lagging chromosomes and cell cycle arrest and cell death in prometaphase. Furthermore, PI3K inhibitors promoted nocodazole-induced mitotic cell death and reduced mitotic slippage. Overexpression of Akt (the downstream target of PI3K) antagonized PI3K inhibitor-induced mitotic cell death and promoted nocodazole-induced mitotic slippage. These results suggest a novel role for the PI3K pathway in regulating mitotic progression and preventing mitotic cell death and provide justification for the use of PI3K inhibitors in combination with anti-mitotic drugs to combat cancer.     

Manipulation of Cardiac Phosphatidylinositol 3-Kinase (PI3K)/Akt Signaling by Apoptosis Regulator through Modulating IAP Expression (ARIA) Regulates Cardiomyocyte Death during Doxorubicin-induced Cardiomyopathy

PI3K/Akt signaling plays an important role in the regulation of cardiomyocyte death machinery, which can cause stress-induced cardiac dysfunction. Here, we report that apoptosis regulator through modulating IAP expression (ARIA), a recently identified transmembrane protein, regulates the cardiac PI3K/Akt signaling and thus modifies the progression of doxorubicin (DOX)-induced cardiomyopathy. ARIA is highly expressed in the mouse heart relative to other tissues, and it is also expressed in isolated rat cardiomyocytes. The stable expression of ARIA in H9c2 cardiac muscle cells increased the levels of membrane-associated PTEN and subsequently reduced the PI3K/Akt signaling and the downstream phosphorylation of Bad, a proapoptotic BH3-only protein. When challenged with DOX, ARIA-expressing H9c2 cells exhibited enhanced apoptosis, which was reversed by the siRNA-mediated silencing of Bad. ARIA-deficient mice exhibited normal heart morphology and function. However, DOX-induced cardiac dysfunction was significantly ameliorated in conjunction with reduced cardiomyocyte death and cardiac fibrosis in ARIA-deficient mice. Phosphorylation of Akt and Bad was substantially enhanced in the heart of ARIA-deficient mice even after treatment with DOX. Moreover, repressing the PI3K by cardiomyocyte-specific expression of dominant-negative PI3K (p110α) abolished the cardioprotective effects of ARIA deletion. Notably, targeted activation of ARIA in cardiomyocytes but not in endothelial cells reduced the cardiac PI3K/Akt signaling and exacerbated the DOX-induced cardiac dysfunction. These studies, therefore, revealed a previously undescribed mode of manipulating cardiac PI3K/Akt signaling by ARIA, thus identifying ARIA as an attractive new target for the prevention of stress-induced myocardial dysfunction.     

PI3K inhibition potentiates Bcl‐2‐dependent apoptosis in renal carcinoma cells

Inhibitors of PI3‐K/Akt are currently being assessed clinically in patients with advanced RCC. Identification of therapeutic strategies that might enhance the efficacy of PI3‐K/Akt inhibitors is therefore of great interest. As PI3‐K inhibition would be expected to have many pro‐apoptotic effects, we hypothesized that there may be unique synergy between PI3‐K inhibitors and BH3‐mimetics. Towards this end, we assessed the combination of the PI3K inhibitor LY 294002 and the Bcl‐2 family inhibitor ABT‐737 in RCC cell lines. We found that the combinatorial treatment with these agents led to a significant increase in PARP cleavage and cell death in all RCC cell lines. The synergized cell death was correlated with decreased levels of Mcl‐1 and XIAP, and increased levels in Bim, and appears critically dependent upon the activation of caspase 3 and 8. The enhanced lethality observed with the combination also appears dependent upon the regulation of XIAP, Mcl‐1 and Bim levels. Our results suggest that the combination of PI3‐K inhibitors with BH3‐mimetics may be a viable therapeutic strategy in RCC.     

磷脂酰肌醇 -3 激酶不直接调控PC12 细胞的分泌

磷脂酰肌醇-3激酶(PI3K)是磷脂酰肌醇代谢过程中一种重要的酶,通过其代谢产物参与了对多种细胞生理活动的调节,如囊泡运输、细胞骨架重组、细胞存活、吞噬作用、细胞凋亡等.为研究其对细胞分泌功能的作用,使用磷脂酰肌醇-3激酶家族的特异性抑制剂渥曼青霉素(wortmannin)阻断磷脂酰肌醇-3激酶的活性,以EGFP-2xFYVE融合蛋白与磷脂酰肌醇-3-磷酸(PtdIns-3-P)的结合为指征,使用荧光显微成像技术检测渥曼青霉素对磷脂酰肌醇-3激酶的抑制作用,采用膜片钳膜电容测量方法及光解钙离子释放技术检测渥曼青霉素对PC12细胞分泌功能的影响.实验结果表明,wortmannin阻断了磷脂酰肌醇-3激酶的活性,抑制了磷脂酰肌醇-3-磷酸(PtdIns-3-P)的产生,并使FYVE与PtdIns-3-P解离,但渥曼青霉素处理之前和处理30 min后的PC12细胞分泌反应的幅度、动力学特性和分泌的钙依赖性均无显著差异,表明磷脂酰肌醇-3激酶对PC12细胞的分泌无显著的直接影响.     

Pik3ip1 Modulates Cardiac Hypertrophy by Inhibiting PI3K Pathway

Cardiac hypertrophy is an adaptive response to various physiological and pathological stimuli. Phosphoinositide-3 kinase (PI3K) is a highly conserved lipid kinase involved in physiological cardiac hypertrophy (PHH). PI3K interacting protein1 (Pik3ip1) shares homology with the p85 regulatory subunit of PI3K and is known to interact with the p110 catalytic subunit of PI3K, leading to attenuation of PI3K activity in liver and immune cells. However, the role of Pik3ip1 in the heart remains unknown. In the present study, the effects of Pik3ip1 on cardiac hypertrophy were examined. We found that the expression level of Pik3ip1 was markedly higher in cardiomyocytes than in fibroblasts. The interaction of Pik3ip1 with the p110a subunit of PI3K in the heart was identified by immunoprecipitation using neonatal rat cardiomyocytes (NRCM). Approximately 35% knockdown of Pik3ip1 was sufficient to induce myocardial hypertrophy. Pik3ip1 deficiency was shown to lead to activation of PI3K/protein kinase B (AKT)/ mammalian target of rapamycin (mTOR) signaling pathway, increasing protein synthesis and cell size. However, adenovirus-mediated overexpression of Pik3ip1 attenuated PI3K-mediated cardiac hypertrophy. Pik3ip1 was upregulated by PHH due to swimming training, but not by pathological cardiac hypertrophy (PAH) due to pressure-overload, suggesting that Pik3ip1 plays a compensatory negative role for PHH. Collectively, our results elucidate the mechanisms for the roles of Pik3ip1 in PI3K/AKT signaling pathway.     

Effects of tyroserleutide on gene expression of calmodulin and PI3K in hepatocellular carcinoma

Tyroserleutide (YSL) is a tripeptide compound that has exhibited inhibitory effects on hepatocellular carcinoma in our previous research. The mechanism of this antitumor activity involves the second messenger, Ca(2+). Ca(2+) influences cell function through the Ca(2+)/calmodulin (CaM) pathway, and abnormality of the Ca(2+)/CaM system correlates closely with the occurrence of tumors. In addition, CaM associates with phosphatidylinositol 3 kinase (PI3K), thereby enhancing the activity of PI3K, which promotes cell proliferation. In order to investigate its anti-tumor mechanism, we studied the effects of YSL on CaM protein expression and mRNA level, PI3K activity, PI3K regulatory subunit p85 protein expression and mRNA level, and the mRNA level of PI3K catalytic subunits p110alpha and p110gamma in human hepatocellular carcinoma BEL-7402 xenograft tumors in nude mice. Our results showed that YSL decreased the mRNA level and protein expression of CaM, inhibited the activity of PI3K, and reduced the mRNA level and protein expression of the PI3K regulatory subunit p85 and mRNA level of PI3K catalytic subunits p110alpha and p110gamma. Accordingly, it is suggestive that the anti-tumor effects of YSL may be mediated by down regulation of CaM and PI3K subunits p85 and p110, influencing the signal transduction pathway in the tumor cells and perhaps overcoming the dysfunctional PI3K activity in tumors.